Skip to Content


Class: Dihydropyridines
VA Class: CV200
Chemical Name: Methyl 2-methylpropyl ester 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid
Molecular Formula: C20H24N2O6
CAS Number: 63675-72-9
Brands: Sular


Calcium-channel blocking agent; dihydropyridine derivative.1 2 3 4 5 6 8 9 10 11 12 42 45

Uses for Nisoldipine


Management of hypertension (alone or in combination with other classes of antihypertensive agents).1 11 12 50

Slideshow: Love Your Dad? Here's 10 Heart-Healthy Gifts For Father's Day

One of several preferred initial therapies in hypertensive patients with a high risk of developing CAD, including those with diabetes mellitus.75

Can be used as monotherapy for initial management of uncomplicated hypertension; however, thiazide diuretics are preferred by JNC 7.75

Should not be used for acute management of hypertensive crises.13 46 50

Nisoldipine Dosage and Administration


Oral Administration

Administer orally;1 2 3 5 6 7 8 11 12 42 avoid concomitant administration with high-fat food.1 42

Extended-release tablets should be swallowed intact and should not be chewed, broken, or crushed.1



Extended-release Tablets

Initially, 20 mg once daily.1 42

Increase as tolerated in increments of 10 mg daily at ≥ weekly intervals up to 60 mg once daily.1 42 50 Monitor BP carefully during initial titration or subsequent upward adjustment in dosage.1 50

Usual maintenance dosage is 20–40 mg once daily;1 however, JNC 7 recommends a usual dosage range of 10–40 mg daily.75

Prescribing Limits



Maximum 60 mg daily.1

Special Populations

Hepatic Impairment

Initially, 10 mg daily; monitor BP response closely with each dosage adjustment.1 42

Reduce initial and maintenance dosages in patients with cirrhosis.1

Renal Impairment

Dosage modification not necessary in patients with mild to moderate renal impairment.1

Geriatric Patients

Initially, 10 mg daily; monitor BP response closely with each dosage adjustment.1 42

Cautions for Nisoldipine


  • Known hypersensitivity to nisoldipine or other dihydropyridine-derivative calcium channel blockers.1



Increased Angina and/or AMI

Rarely, increased frequency, duration, and/or severity of angina or AMI, particularly in patients with severe obstructive CAD, upon initiation or dosage increase of calcium channel blockers.1

General Precautions


Risk of excessive, poorly tolerated hypotension; usually occurs during initial dosage titration or subsequent upward titration.1 Carefully monitor BP, especially during therapy initiation, titration, or dosage increase; closely observe patients currently receiving drugs known to lower BP.1


Use with caution in patients with CHF or compromised ventricular function, especially in those receiving concomitant β-adrenergic blocking agents.1

Specific Populations


Category C.1


Not known whether nisoldipine is distributed into milk.1 Discontinue nursing or the drug.1

Pediatric Use

Safety and efficacy not established.1

Geriatric Use

Insufficient experience in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults.1 Select dosage with caution.1 (See Geriatric Patients under Dosage and Administration.)

Hepatic Impairment

Use with caution in patients with severe hepatic impairment.1 Dosage reduction required.1 (See Hepatic Impairment under Dosage and Administration.)

Common Adverse Effects

Peripheral edema, headache, dizziness, pharyngitis, vasodilation, sinusitis, palpitation, chest pain, nausea, rash.1

Interactions for Nisoldipine

Drugs Affecting Hepatic Microsomal Enzymes

Inducers of CYP3A4: Decreased plasma nisoldipine concentrations.1 a Avoid concomitant use.1 a

Specific Drugs and Foods

Drug or Food



β-Adrenergic blocking agents

Increased risk of hypotension and exacerbation of CHF1


Pharmacokinetic interaction unlikely1

Grapefruit juice

Increased nisoldipine bioavailability1

Avoid grapefruit-containing foods and beverages for at least 1 hour before and after administration of a dose1 44 46

Histamine H2-receptor antagonists

Possible increased nisoldipine concentrations with cimetidine; no significant interaction with ranitidine1


Decreased plasma concentrations of nisoldipine to undetectable levels1

Avoid concomitant use1


Possible decreased AUC of nisoldipine1

Clinical significance unknown1


Pharmacokinetic interaction unlikely1

Nisoldipine Pharmacokinetics



Relatively well absorbed from the GI tract following oral administration,1 a with peak plasma concentrations attained within 6–12 hours.1

Absolute bioavailability is low (about 5%), due to presystemic metabolism in the intestine; presystemic metabolism decreases from proximal to distal parts of intestine.1 a b Bioavailability of extended-release preparation is increased since nisoldipine is released in the colon where presystemic metabolism is reduced.1 a b


A high-fat meal increases peak plasma concentrations by about 300%, but decreases extent of absorption by 25% (since more of the drug is released proximally).1

Special Populations

In geriatric patients, plasma concentrations increased about 2- to 3-fold.1

In patients with hepatic cirrhosis, plasma concentrations increased by 4–5 times.1



Not known whether nisoldipine is distributed into milk.1

Plasma Protein Binding

>99%.1 a



Thought to be metabolized principally by CYP isoenzymes.1 Precise enzymes responsible for metabolism are unknown, but other dihydropyridine-derivative calcium-channel blocking agents are metabolized by CYP3A4.1

Elimination Route

Excreted principally in urine (60–80%) as metabolites.1


Approximately 7–12 hours.1 a





Tight, light-resistant containers at 20–25°C.1 Protect from light and moisture.1


  • Inhibits transmembrane influx of extracellular calcium ions across the membranes of myocardial cells and vascular smooth muscle cells.1

  • Peripheral arterial vasodilator; acts directly on vascular smooth muscle causing reduction in peripheral vascular resistance (afterload) and BP.1

Advice to Patients

  • Importance of swallowing extended-release tablets whole; do not chew, crush, or break.1

  • Importance of avoiding administration with a high-fat meal.1

  • Importance of avoiding grapefruit-containing foods and beverages for at least 1 hour before and after administration of a dose.1 44 46

  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.1

  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.1

  • Importance of informing patients of other important precautionary information.1 (See Cautions.)


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.



Dosage Forms


Brand Names



Tablets, extended-release, film-coated

10 mg


First Horizon

20 mg


First Horizon

30 mg


First Horizon

40 mg


First Horizon

Comparative Pricing

This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 02/2014. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.

Nisoldipine 17MG 24-hr Tablets (MYLAN): 30/$189.98 or 90/$539.96

Nisoldipine 20MG 24-hr Tablets (MYLAN): 30/$200.00 or 90/$575.95

Nisoldipine 25.5MG 24-hr Tablets (MYLAN): 30/$218.00 or 90/$623.99

Nisoldipine 30MG 24-hr Tablets (MYLAN): 30/$219.00 or 90/$614.97

Nisoldipine 40MG 24-hr Tablets (MYLAN): 30/$220.48 or 90/$616.47

Nisoldipine 8.5MG 24-hr Tablets (MYLAN): 30/$156.98 or 90/$438.95

Sular 17MG 24-hr Tablets (SHIONOGI PHARMA): 100/$1,000.01 or 300/$2,995.08

Sular 25.5MG 24-hr Tablets (SHIONOGI PHARMA): 100/$939.54 or 300/$2,807.02

Sular 34MG 24-hr Tablets (SHIONOGI PHARMA): 100/$905.00 or 300/$2,702.64

Sular 8.5MG 24-hr Tablets (SHIONOGI PHARMA): 100/$658.92 or 300/$1,959.49

AHFS DI Essentials. © Copyright, 2004-2016, Selected Revisions March 1, 2007. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.


1. First Horizon.Sular (nisoldipine) extended-release tablets prescribing information. (dated 2004 Mar). In: Physicians' desk reference. From the PDR electronic library website. Accessed 2006 Nov 9.

2. Zannad F. Clinical pharmacology of nisoldipine coat core. Am J Cardiol. 1995; 75:41-5E.

3. Mitchell J, Frishman W, Heiman M. Nisoldipine: a new dihydropyridine calcium-channel blocker. J Clin Pharmacol. 1993; 33:46-52. [IDIS 308542] [PubMed 8429113]

4. Knorr AM. Why is nisoldipine a specific agent in ischemic left ventricular dysfunction? Am J Cardiol. 1995; 75:36-40E.

5. Fujii Y, Hattori S, Nagami K et al. The hypotensive effect of nisoldipine: 24-hour blood pressure profile and serial alterations of renal and hormonal function. Curr Ther Res. 1994; 55:93-101.

6. Ishiguro M, Shimabukuro S, Minagawa T et al. Evaluation of nisoldipine by noninvasive ambulatory blood pressure monitoring in patients with hypertension. Curr Ther Res. 1991; 50:804-11.

7. Nakanishi T, Takahashi H, Yoshimura M et al. Effects of nisoldipine on ambulatory blood pressure in patients with essential hypertension. Curr Ther Res. 1991; 50:417-24.

8. Shionoiri H, Sugiyama K, Takasaki I et al. Antihypertensive effects of nisoldipine in patients with essential hypertension. Curr Ther Res. 1989; 45:253-61.

9. Lewis BS. Efficacy and safety of nisoldipine coat core in the management of angina pectoris, systemic hypertension, and ischemic ventricular dysfunction. Am J Cardiol. 1995; 75:46E-53E. [IDIS 348305] [PubMed 7726125]

10. Glasser SP. Nisoldipine coat core as concomitant therapy in chronic stable angina pectoris. Am J Cardiol. 1995; 75:68-70E.

11. Shaw-Stiffel TA, Walker SE, Ogilvie RI et al. Pharmacokinetic and pharmacodynamic interactions during multiple-dose administration of nisoldipine and propranolol. Clin Pharmacol Ther. 1994; 55:661-9. [IDIS 331942] [PubMed 8004882]

12. Rosenfeld JB, Zabludowski J. The efficacy and tolerability of nifedipine (NIF) and nisoldipine (NIS) both alone and combined with a beta-blocker in patients with essential hypertension: a multicenter, parallel-group study. J Clin Pharmacol. 1989; 29:1013-16. [IDIS 261842] [PubMed 2574728]

13. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993; 153:154-83. [IDIS 309043] [PubMed 8422206]

14. Alderman MH. Which antihypertensive drugs first—and why! JAMA. 1992; 267:2786-7. Editorial.

15. Glasser SP, Clark PI, Lipicky RJ et al. Exposing patients with chronic, stable, exertional angina to placebo periods in drug trials. JAMA. 1991; 265:1550-4. [PubMed 1671885]

16. National Heart, Lung, and Blood Institute. NHLBI panel reviews safety of calcium channel blockers. Rockville, MD; 1995 Aug 31. Press release.

17. National Heart, Lung, and Blood Institute. New analysis regarding the safety of calcium-channel blockers: a statement for health professionals from the National Heart, Lung, and Blood Institute. Rockville, MD; 1995 Sep 1.

18. Anon. NHLBI panel stands by JNC V in response to Circulation CCB article; AIM report supports use of beta blockers for prevention of sudden cardiac death. F-D-C Rep. 1995; 57(Sep 4):3- 4.

19. American Heart Association. Public advisory statement on calcium channel blocker drugs. Dallas, TX; 1995 Aug 28.

20. Psaty BM, Heckbert SR, Koepsell TD et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995; 274:620-5. [IDIS 352203] [PubMed 7637142]

21. Psaty BM, Heckbert SR, Koepsell TD et al. The risk of incident myocardial infarction associated with anti-hypertensive drug therapies. Circulation. 1995; 91:925.

22. Buring JE, Glynn RJ, Hennekens CH. Calcium channel blockers and myocardial infarction: a hypothesis formulated but not yet tested. JAMA. 1995; 274:654- 5. [IDIS 352205] [PubMed 7637148]

23. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995; 92:1326-31. [IDIS 353358] [PubMed 7648682]

24. Opie LH, Messerli FH. Nifedipine and mortality: grave defects in the dossier. Circulation. 1995; 92:1068-73. [IDIS 353353] [PubMed 7648646]

25. Kloner RA. Nifedipine in ischemic heart disease. Circulation. 1995; 92:1074-8. [IDIS 353354] [PubMed 7648647]

26. Yusuf S. Calcium antagonists in coronary artery disease and hypertension: time for reevaluation? Circulation. 1995; 92:1079-82. Editorial.

27. Lenfant C. The calcium channel blocker scare: lessons for the future. Circulation. 1995; 91:2855-6. [PubMed 7796490]

28. Habib GB. Are calcium antagonists harmful in hypertensive patients? Distinguishing hype from reality. Chest. 1995; 108:3-5. [IDIS 351406] [PubMed 7606987]

29. Horton R. Spinning the risks and benefits of calcium antagonists. Lancet. 1995; 346:586- 7. [IDIS 353102] [PubMed 7650997]

30. Yusuf S, Held P, Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the Second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol. 1991; 67:1295-7. [IDIS 284079] [PubMed 2035457]

31. Egstrup K, Andersen PE Jr. Transient myocardial ischemia during nifedipine therapy in stable angina pectoris, and its relation to coronary collateral flow and comparison with metoprolol. Am J Cardiol. 1993; 71:177- 83. [IDIS 308552] [PubMed 8421980]

32. Wagenknecht LE, Furberg CD, Hammon JW et al. Surgical bleeding: unexpected effect of a calcium antagonist. BMJ. 1995; 310:776-7. [IDIS 345035] [PubMed 7711582]

33. Miles Inc. American Heart Association, Dr. Psalty and Miles Inc. release statements qualifying possible risks of calcium channel blockers. West Haven, CT; 1995 Mar 15. Press release.

34. Dear healthcare professional letter regarding calcium-channel blockers and increased risk of heart attack. Chicago: Searle. 1995 Mar 17.

35. McClellan K. Unexpected results from MIDAS in atherosclerosis. Inpharma Wkly. 1994; Apr 9:4.

36. Anon. Groups act to dispel concerns about calcium-channel blockers. Am J Health-Syst Pharm. 1995; 52:1154, 1158. [PubMed 7656105]

37. Waters D. Proischemic complications of dihydropyridine calcium channel blockers. Circulation. 1991; 84:2598-600. [IDIS 295953] [PubMed 1959210]

38. Messerli FH. Case-control study, meta-analysis, and bouillabaisse: putting the calcium antagonist scare into context. Ann Intern Med. 1995; 123:888-9. [IDIS 356631] [PubMed 7486476]

39. Reviewers’ comments (personal observations) on Nifedipine 24:28.

40. Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ. 1989; 299:1187-92. [IDIS 260789] [PubMed 2513047]

41. Weber MA, Laragh JH. Hypertension: steps forward and steps backward: the Joint National Committee fifth report. Arch Intern Med. 1993; 153:149-52. [PubMed 8422205]

42. Anon. Nisoldipine—a new calcium channel blocker for hypertension. Med Lett Drugs Ther. 1996; 38:13-4. [PubMed 8592476]

43. Anon. grapefruit juice interactions with drugs. Med Lett Drugs Ther. 1995; 37:73-4. [PubMed 7630329]

44. Bailey DG, Arnold JMO, Strong HA et al. Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics. Clin Pharmacol Ther. 1993; 54:589-94. [IDIS 324230] [PubMed 8275614]

45. Kaplan NM, Gifford RW. Choice of initial therapy for hypertension. JAMA. 1996; 275:1577-9. [IDIS 365188] [PubMed 8622249]

46. Zeneca Pharmaceuticals, Wilmington, DE: Personal communication.

47. Chandler MHH, Clifton GD, Lettieri JT et al. Multiple dose pharmacokinetics of four different doses of nisoldipine in hypertensive patients. J Clin Pharmacol. 1992; 32:571-5. [IDIS 298488] [PubMed 1634646]

48. Marazzi P. A study to demonstrate the equivalence in efficacy and safety of once-daily nisoldipine CC and amlodipine in the treatment of mild to moderate hypertension. Acta Ther. 1996; 22:23-35.

49. Lasseter KC, Muller FO, Garrett BN et al. Pharmacokinetics, pharmacodynamics, and clinical utility of nisoldipine coat core in the treatment of essential hypertension. Cardiovasc Rev Rep. 1996; 17:28,31-35,38,44-46.

50. National Heart, Lung, and Blood Institute National High Blood Pressure Education Program. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Bethesda, MD: National Institutes of Health; 1997 Nov. (NIH publication No. 98-4080.)

51. Kaplan NM. Choice of initial therapy for hypertension. JAMA. 1996; 275:1577-80. [IDIS 365188] [PubMed 8622249]

52. Psaty BM, Smith NL, Siscovich DS et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA. 1997; 277:739-45. [IDIS 380501] [PubMed 9042847]

53. American College of Cardiology and American Heart Association. ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol. 1996; 28:1328-428. [IDIS 376249] [PubMed 8890834]

54. Staessen JA, Fagard R, Thijs L et al for the Systolic Hypertension-Europe (Syst-Eur) Trial Investigators. Morbidity and mortality in the placebo-controlled European Trial on Isolated Systolic Hypertension in the Elderly. Lancet. 1997; 350:757-64. [IDIS 392056] [PubMed 9297994]

55. Estacio RO, Jeffers BW, Hiatt WR et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998; 338:645-52. [IDIS 400553] [PubMed 9486993]

56. Pahor M, Psaty BM, Furberg CD. Treatment of hypertensive patients with diabetes. Lancet. 1998; 351:689-90. [IDIS 409001] [PubMed 9504510]

57. Tatti P, Pahor M, Byington RP et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998; 21:597-603. [IDIS 403787] [PubMed 9571349]

58. Byington RP, Craven TE, Furberg CD et al. Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events. Lancet. 1997; 350:1075-6. [IDIS 393279] [PubMed 10213554]

59. Alderman M, Madhavan S, Cohen H. Calcium antagonists and cardiovascular events in patients with hypertension and diabetes. Lancet. 1998; 351:216-7. [IDIS 398935] [PubMed 9449897]

60. Josefson D. Infarction risk found with calcium channel blocker. BMJ. 1998; 316:797.

61. Cutler JA. Calcium-channel blockers for hypertension—uncertainty continues. N Engl J Med. 1998; 338:679-81. [IDIS 400554] [PubMed 9486999]

62. Bayer, West Haven, CT: Personal communication.

63. Bakris GL, Copley JB, Vicknair N et al. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int. 1996; 50:1641-50. [PubMed 8914031]

64. Velussi M, Brocco E, Frigato F et al. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes. 1996; 45:216-22. [IDIS 362953] [PubMed 8549868]

65. Reviewers’ comments (personal observations).

66. Ameer B, Weintraub RA. Drug interactions with grapefruit juice. Clin Phramacokinet. 1997; 33:103-21.

67. Roller L. Drugs and grapefruit juice. Clin Pharmacol Ther. 1998; 63:87. [IDIS 398865] [PubMed 9465845]

68. Spence JD. Drugs and grapefruit juice. Clin Pharmacol Ther. 1998; 63:87-8. [IDIS 398865] [PubMed 9465845]

69. Izzo JL, Levy D, Black HR. Importance of systolic blood pressure in older Americans. Hypertension. 2000; 35:1021-4. [PubMed 10818056]

70. Frohlich ED. Recognition of systolic hypertension for hypertension. Hypertension. 2000; 35:1019-20. [PubMed 10818055]

71. Bakris GL, Williams M, Dworkin L et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000; 36:646-61. [IDIS 452007] [PubMed 10977801]

72. Associated Press (American Diabetes Association). Diabetics urged: drop blood pressure. Chicago, IL; 2000 Aug 29. Press Release from web site.

73. Appel LJ. The verdict from ALLHAT—thiazide diuretics are the preferred initial therapy for hypertension. JAMA. 2002; 288:3039-60. [IDIS 490723] [PubMed 12479770]

74. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-riskhypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288:2981-97. [IDIS 490721] [PubMed 12479763]

75. National Heart, Lung, and Blood Institute National High Blood Pressure Education Program. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VII) Express. Bethesda, MD: May 14 2003. From NIH website. (Also published in JAMA. 2003; 289.

76. American Diabetes Association. Position statements: treatment of hypertension in adults with diabetes. Diabetes Care. 2003; 26(Suppl 1):S80-S82.

77. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care. 2003; 26(Suppl 1):S80-2.

78. Guidelines Committee. 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertension. 2003; 21:1011-53.

79. Carter B for the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Personal communication.

80. Wright JT, Dunn JK, Cutler JA et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005; 293:1595-607. [IDIS 531054] [PubMed 15811979]

81. Neaton JD, Kuller LH. Diuretics are color blind. JAMA. 2005; 293:1663-6. [IDIS 531056] [PubMed 15811986]

82. Leenen FHH, Nwachuku CE, Black HR et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium-channel blocker versus angiotensin-converting enzyme inhibitor in the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial. Hypertension. 2006; 48:374-84. [PubMed 16864749]

83. Messerli FH, Staessen JA. Amlodipine better than lisinopril: how one randomized clinical trial ended fallacies from observational studies? Hypertension. 2006; 48:359-61. Editorial.

a. Heinig R. Clinical pharmacokinetics of nisoldipine coat-core. Clin Pharmacokinet. 1998; 35:191-208. [PubMed 9784933]

b. Heinig R. Ahr G, Hayauchi Y et al. Pharmacokinetics of the controlled-release nisoldipine coat-core tablet formulation. Int J Clin Pharmacol. 1997; 35:341-51.